AXER-204 in Participants With Chronic Spinal Cord Injury (RESET Trial)
Palo Alto (17 mi)Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 1 & 2
Waitlist Available
Sponsor: ReNetX Bio, Inc.
Trial Summary
What is the purpose of this trial?This two-part trial will assess the safety, tolerability, pharmacokinetics, and efficacy of AXER-204 administered by lumbar puncture and slow bolus infusion. Part 1 will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of AXER-204. Part 2 will evaluate the safety, tolerability, pharmacokinetics, and efficacy of repeated doses AXER-204 in comparison to placebo.
Eligibility Criteria
Treatment Details
2Treatment groups
Experimental Treatment
Placebo Group
Group I: AXER-204Experimental Treatment1 Intervention
Part 1 - Single ascending doses; Part 2 - Repeated dose
Group II: PlaceboPlacebo Group1 Intervention
Part 2 only - Repeated dose
Find a clinic near you
Research locations nearbySelect from list below to view details:
Thomas Jefferson UniversityPhiladelphia, PA
The Ohio State University Wexner Medical CenterColumbus, OH
Keck Medicine of USCLos Angeles, CA
Shepherd CenterAtlanta, GA
More Trial Locations
Loading ...
Who is running the clinical trial?
ReNetX Bio, Inc.Lead Sponsor